Physician profile
Mona Kaur
NPI 1174072193
$4,735.58
in general payments reported to CMS, 2019-2025
25 companies · $788 in 2025
The $788 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,043 · 2022: $943 · 2023: $1,030 · 2024: $932 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,741.50 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,552.81 | 2021-2025 | |
| Novo Nordisk INC | $1,197.63 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $446.17 | 2021-2025 | |
| Glaxosmithkline, LLC. | $401.51 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $146.26 | 2021-2025 | Prolia, Evenity |
| Astellas Pharma US INC | $143.27 | 2022-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.83 | 2022-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $105.11 | 2022-2025 | |
| Biohaven Pharmaceuticals, INC. | $93.81 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $91.67 | 2021-2025 | Farxiga |
| Axsome Therapeutics, INC. | $74.04 | 2025 | Auvelity |
| Dexcom, INC. | $71.21 | 2023-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $64.18 | 2021-2025 | Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $44.71 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.06 | 2023-2025 | Jardiance, Synjardy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.10 | 2023 | Watchman Access System |
| Sanofi-Aventis U.S. LLC | $21.58 | 2022 | |
| Antares Pharma, INC. | $19.94 | 2024 | Xyosted |
| Philips North America LLC | $18.81 | 2024 | (Ck6) Holter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.12 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $14.36 | 2023 | Nuedexta |
| Watermark Medical, INC. | $14.12 | 2024 | |
| Seqirus USA INC | $13.35 | 2021 | |
| Sanofi Pasteur INC. | $13.29 | 2022 | |
| Genentech USA, INC. | $2.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.